CD274 and neoplasm: The combination remodeled the tumor microenvironment to a more immune-active form via reprogramming TAMs (most notably, the significant change in the PD-L1-positive TAM subpopulation), uniformly downregulating PD-L1 expression, and restoring T cell populations, which cannot be achieved by gemcitabine or α-PD-L1 antibody alone.